ATE499385T1 - Tumornekrosefaktor-alpha spezifische humanisierte antikörper - Google Patents

Tumornekrosefaktor-alpha spezifische humanisierte antikörper

Info

Publication number
ATE499385T1
ATE499385T1 AT05823880T AT05823880T ATE499385T1 AT E499385 T1 ATE499385 T1 AT E499385T1 AT 05823880 T AT05823880 T AT 05823880T AT 05823880 T AT05823880 T AT 05823880T AT E499385 T1 ATE499385 T1 AT E499385T1
Authority
AT
Austria
Prior art keywords
humanized antibodies
alpha
necrosis factor
tumor necrosis
specific humanized
Prior art date
Application number
AT05823880T
Other languages
English (en)
Inventor
Tae Hyoung Yoo
Moo Young Song
Chang Seok Kim
Sang Koo Park
Kang In Na
Byung Kyu Lee
Heui Il Kang
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Application granted granted Critical
Publication of ATE499385T1 publication Critical patent/ATE499385T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05823880T 2004-12-29 2005-12-29 Tumornekrosefaktor-alpha spezifische humanisierte antikörper ATE499385T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040115709 2004-12-29
PCT/KR2005/004634 WO2006071091A1 (en) 2004-12-29 2005-12-29 Humanized antibody specific for tumor necrosis factor-alpha

Publications (1)

Publication Number Publication Date
ATE499385T1 true ATE499385T1 (de) 2011-03-15

Family

ID=36615169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823880T ATE499385T1 (de) 2004-12-29 2005-12-29 Tumornekrosefaktor-alpha spezifische humanisierte antikörper

Country Status (9)

Country Link
US (1) US7645450B2 (de)
EP (1) EP1831257B9 (de)
JP (1) JP4642862B2 (de)
KR (1) KR100971497B1 (de)
CN (1) CN101111521B (de)
AT (1) ATE499385T1 (de)
DE (1) DE602005026571D1 (de)
ES (1) ES2359567T3 (de)
WO (1) WO2006071091A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
DK2119452T3 (da) * 2006-12-26 2020-04-20 Ct Inmunologia Molecular Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis
WO2008141511A1 (fr) * 2007-05-22 2008-11-27 Human Antibodomics (Shanghai) Inc. ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION
WO2010105446A1 (zh) * 2009-03-20 2010-09-23 上海宏源生物技术有限公司 抗人肿瘤坏死因子受体α单抗及其应用
CL2010000019A1 (es) * 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
JP6009441B2 (ja) * 2010-06-22 2016-10-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ハイブリッド軽鎖マウス
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
CN102464718B (zh) * 2010-11-05 2014-08-13 财团法人工业技术研究院 人源化之单克隆抗体、其氨基酸序列与核苷酸序列与其用途
US8658171B2 (en) 2011-02-28 2014-02-25 Livzon Mabpharm Inc. Humanized anti-TNFα antibodies
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
WO2013125221A1 (ja) * 2012-02-21 2013-08-29 静岡県 抗体精製用アフィニティリガンド
US10488075B2 (en) * 2013-06-18 2019-11-26 B/E Aerospace, Inc. Apparatus for pre-heating potable water in aircraft with waste heat
CN105294861B (zh) * 2015-11-26 2019-02-19 深圳万乐药业有限公司 亲和层析纯化抗肿瘤坏死因子α单克隆抗体的方法
RS61883B1 (sr) * 2017-09-19 2021-06-30 Tillotts Pharma Ag Varijante antitela
EP3456738B1 (de) * 2017-09-19 2024-07-17 Tillotts Pharma Ag Antikörpervarianten
CN110642946A (zh) * 2019-09-30 2020-01-03 中国药科大学 一种人源化纳米抗体及其制备方法
CN111153994B (zh) * 2019-12-31 2021-10-15 武汉班科生物技术股份有限公司 人肿瘤坏死因子的人源单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0614984B2 (de) * 1993-03-05 2010-11-03 Bayer HealthCare LLC Humane monoklonale anti-TNF alpha Antikörper
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CN1225479C (zh) * 2002-12-23 2005-11-02 马菁 肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자

Also Published As

Publication number Publication date
US20080008703A1 (en) 2008-01-10
JP2008525048A (ja) 2008-07-17
EP1831257A4 (de) 2008-12-24
ES2359567T9 (es) 2011-05-25
KR100971497B1 (ko) 2010-07-21
US7645450B2 (en) 2010-01-12
EP1831257B1 (de) 2011-02-23
CN101111521B (zh) 2011-08-24
EP1831257B9 (de) 2011-05-04
WO2006071091A1 (en) 2006-07-06
KR20060076247A (ko) 2006-07-04
CN101111521A (zh) 2008-01-23
DE602005026571D1 (de) 2011-04-07
JP4642862B2 (ja) 2011-03-02
ES2359567T3 (es) 2011-05-24
EP1831257A1 (de) 2007-09-12

Similar Documents

Publication Publication Date Title
ATE499385T1 (de) Tumornekrosefaktor-alpha spezifische humanisierte antikörper
JP2016135783A5 (de)
DE60329489D1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
HK1038069A1 (en) Immunoassay for c.reactive protein
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
HRP20171274T1 (hr) U potpunosti ljudska antitijela specifična za cadm1
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ATE452147T1 (de) Antikörper mit korrigierten cdr
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
JP2008516970A5 (de)
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
RS52484B (en) CD40 ANTIBODIES
RS52452B (en) Antibodies and Immunoconjugates and Their Use
HRP20090228T1 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
MY147257A (en) Polypeptides and antibodies
NZ607711A (en) Antibodies directed to her-3 and uses thereof
WO2010027488A3 (en) Monoclonal antibodies
WO2010132659A3 (en) Anti-human cd52 immunoglobulins
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
NZ585622A (en) Hepatitis c virus antibodies
SA522440646B1 (ar) أجسام مضادة ترتبط بـ siglec15 واستخداماتها

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1831257

Country of ref document: EP